Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT02889016
Status
Recruiting

Conditions

  • PANDAS
  • PANS
  • Pediatric Acute-Onset Neuropsychiatric Syndrome
  • Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections

Eligibility Criteria

Sex
ALL
Age
4 Years - 18 Years
Healthy Volunteers
Accepted

Study Details

This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a condition characterized by the abrupt, dramatic onset of obsessive compulsive disorder (OCD) and/or eating restriction accompanied by equally abrupt and severe co-morbid neuropsychiatric symptoms, which include anxiety, emotional lability, depression, irritability, aggression, oppositionality, deterioration in school performance, behavioral (developmental) regression, sensory amplification, movement abnormalities, sleep disturbance, and urinary frequency. PANS is thought to be caused by infection, inflammation, or alternate triggers that is associated with a brain response that leads to these symptoms. The purpose of this study is to examine specific neurologic, immunologic, rheumatologic, and genomic, components in children with the acute-onset of psychiatric symptoms. This research may begin to uncover a much larger story of autoimmune processes that are involved in psychiatric disorders of childhood. By better understanding the etiologic components of psychiatric phenomenon, future treatments may be better targeted to underlying causes.

Key Dates

Start date
Mar 31, 2013
Status verified
Oct 2016
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: PANS group
    500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
  • Arm: Health Controls
    100 healthy children age- and gender- matched to the PANS group will be recruited

Primary Outcome Measure

Cerebral blood flow [ Time Frame: Through study completion, up to 12 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityPalo AltoCalifornia94305-5906
Joanne Cheung

Find similar trials in Palo Alto, CA

Related Studies